To gain an insight in the regulation of (24jR)-hydroxycalcidiol, we studied the pharmacokinetics of orally administered (24R)-hydroxycalcidiol in 6 healthy subjects without calcium supplementation, in 4 healthy subjects with calcium supplementation and in 6 patients with primary hyperparathyroidism. Various quantities related to calcium and vitamin D metabolism were also monitored.
Introduction
It is generally accepted that calcitriol (1α,25π1ί-hydroxycholecalciferol) represents the biologically active metabolite of vitamin D 3 (1) , while the function of (24A)-hydroxycalcidiol is still controversial. Human pharmacokinetics of (24/?)-hydroxycalcidiol have been studied (2 -5) , but only one of these studies yielded reliable estimates for its clearance and proEur. J. Ctin. Chem. Clin. Biochem. / Vol. 31,1993 / No. 7 duction rate (5) . In vitro and in vivo studies have demonstrated that the activity of rat 24-hydroxylase is modulated by parathyroid hormone (parathyrin) (6) (7) (8) , calcitriol (7) (8) (9) (10) (11) , dietary calcium (7, (10) (11) (12) (13) , and phosphorus (7, 10) . Hence, production rate or clearance of (24/?)-hydroxycalcidiol may be determined by these factors and may reflect abnormalities of calcium and vitamin D 3 metabolism.
To gain insight in the regulation of (24/?)-hydroxycalcidiol in humans, we studied in detail the pharmacokinetics of orally administered (24/?)-hydroxycalcidiol in a) healthy subjects, b) healthy subjects with calcium supplementation, and c) patients with primary hyperparathyroidism.
Experimental
Design of the pharmacokinetic studies After fasting since midnight, 6 healthy males (31 ± 5 a) each received orally 100 μg of (24R)-hydroxycalcidiol. The plasma concentration of this metabolite was determined at t = -1 and 0 h to obtain its basal serum concentration. (24/?)-Hydroxycalcidiol was determined at 2, 3, 5 and 8 h, and at day 1, 2, 3, 6, 10, 13 and 21 after dosing. Calcidiol (25-hydroxycholecalciferol) and calcitriol (la, 25-dihydroxycholecalciferol) were also determined at these times. Serum calcium, phosphate, intact perathyroid hormone (1-84), albumin, creatinine and vitamin D-binding protein were measured at 0 and 8 h and at day 1, 10 and 21. The study was performed in January and February.
Four healthy male subjects (37 ± 9 a) were supplemented for 42 days (January-February) with l g of calcium in the evening (Calcium Sandoz, fortissimum). After an equilibration period of 19 days, 100 μg of (24^?)-hydroxycalcidiol were orally administered in the fasting state. (24A)-Hydroxycalcidiol, calcidiol and calcitriol were determined on the day of administration (day 0) at 0, 2, 3, 5 and 8 h. These metabolites were also determined on day -19, -18, -5, -1, 1, 2, 3,12, 15, and 21. Serum Ca ? Pj and parathyrin were measured on day -19, -18. -5, 0, 1 and 21, and at day 0, i.e. 10 h after dosing.
The design of the study for the patients with primary hyperparathyroidism has already been described in detail (14) .
Materials
Non-labelled vitamin D 3 metabolites and capsules containing 25 μg of (24/?)-hydroxycalcidiol were a generous gift from Duphar (Weesp, The Netherlands). [23, H](24A)-Hydroxycalcidiol, [23, H]calcitriol and [26,27 raethyl-3 H]calcidiol were obtained from the Radiochemical Centre, Amersham, UK. Assays (24y?)-Hydroxycalcidiol, calcidiol and calcitriol were determined as previously described in detail (15) . The vitamin D 2 and vitamin D 3 metabolites were not separated by the Chromatographie system used. Since food is not fortified with vitamin D 2 in The Netherlands, the circulating serum concentrations of the vitamin D 2 metabolites are negligible compared with the serum concentrations of their D 3 counterparts. The samples of each individual were run within one series, to eliminate interassay variations. Quality control samples were run with each analytical series. The intra-assay coefficients of variation were 9.3, 3.0 and 11.1%, respectively. Intact parathyrin (1 -84) was determined by a two-step immunochemical method of Hackeng et al. (16) , vitamin D binding protein was determined by radial immunodiffusion (17) and the other biochemical quantities were determined with standard procedures.
To investigate the specificity of our (24/?)-hydroxycalcidiol assay procedure, the remaining serum from non-supplemented healthy subjects 1 -3 collected at days 2, 3, 5 and 7, was pooled.
Aliquots of these pooled samples were chromatographed on the Chromatographie system used in our assay procedure (15) , the (24-K)-hydroxycalcidiol fractions were collected, the eluent evaporated under a stream of nitrogen and the residue dissolved in 480 μΐ of ethanol. Of this solution 350 μΐ were used to determine (24A)-hydroxycalcidiol; 100 μΐ were rechromatographed on a 30-cm d 8 column (Spherisorb ODS 2) with 95 : 5 methanol-water as eluent (1.0 ml/miri), the (24^)-hydroxycalcidiol fractions were collected (recovery 66%, retention time 7 min), and (24y?)-hydroxycalcidiol was determined again.
Pharmacokinetic analysis
For the non-supplemented healthy subjects, the post-dosing serum concentrations of (24/0-hydroxycaIcidiol were corrected for the basal concentration (C b ) of the metabolite by subtracting the mean of the pre-dosing serum concentrations at t = -1 and 0 h, respectively.
The terminal serum half-time (ti /2 ) was calculated (day 5-21) with a non-linear estimation program (PCNONLIN) (18) . The area under the total plasma concentration vs time curve (AUC) was estimated by numerical integration (linear trapezoidal rule) (19) . The systemic clearance (Cl) was calculated by multiplying the serum elimination rate constant k (0.693/t 1/2 ) by the distribution volume (V d ) (20) ratio (= PRmax/^m) is a measure of the 24^hydroxylase activity. These ratios were also normalized for body weight.
In the calcium-supplemented subjects, the observed pre-dosing trend of (24jR)-hydroxycalcidiol (see Results) was extrapolated to give the basal serum concentrations after dosing. After correction of the measured post-dosing values, the pharmacokinetic values were calculated as already outlined.
Previously we studied the pharmacokinetics of (247?)-hydroxycalcidiol in 18 patients with primary hyperparathyroidism (14) . In 6 of these patients (60 ± 15 a), initial half-time (t I/2%1 ), postdosing half-time (ti /2 .i), production rate (PR) and PR/[calcidiol] ratio normalized for body weight were evaluated. t i/2t , was obtained after correction of the measured serum concentrations for the basal serum concentration at month 3 ( fig. 3 ). t 1/2 .i was estimated from: a) the AUC (month 3-5), applying Cl = F χ D/AUC 3 _ >5 (20) and Cl = (0.693/t I/2J ) χ V d (20) and setting the bioavailability (F) of orally administered (24jR)-hydroxycalcidiol to 0.7 (5); and b) r ss = 1-e~N kT (25) , where r M represents the ratio of the serum concentration reached at month 4 to the (mean) steady-state serum concentration, Ν the number of dosages given up to month 4, k the elimination rate constant (t| /2iJ = 0.693/k) and T the dosing interval (1 day). In the second method, the mean of the serum concentrations at month 5 and 6 was taken as the (mean) steady-state serum concentration. t, /2 , 2 was obtained from the declining portion of the serum concentration vs time curve ( fig. 3) . To obtain the initial production rate PR (PRj) and the post-dosing production rate (PR 2 ), basal concentration at month 3 (C b ,i) and basal concentration at month 9 (C b . 2 ) (see? fig. 3 ) were used. Finally, PR and PR/[calcidiol] ratio were normalized for body weight. To obtain this ratio, the mean of calcidiol during month 3-5 was used.
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Statistical analysis
Significance levels were obtained by applying Student's t-test. P < 0.05 was considered statistically significant.
Results
Rechromatography on the reversed phase Chromatographie system used did not affect the determined concentrations of (24K)-hydroxycalcidiol, indicating that only (24R)-hydroxycalcidiol was determined in our assay procedure for (24R)-hydroxycalcidiol.
In the non-supplemented subjects, the serum concentration vs time curves of (24/?)-hydroxycalcidiol exhibited a second maximum on day 2 -3 ( fig. 1 ). Therefore, the terminal half-time was calculated from day 5 -21. The resulting pharmacokinetic data are summarized in tables 1 and 2. The basal serum concentration of subject 3 (P < 0.01), PR (P < 0.01) and Tab. 1. Pharmacokinetics of (24J?)-hydroxycalcidiol after oral administration of 100 μg to the non-supplemented healthy subjects. ± i.i ) The values at the start of the study are given for the calcium-supplemented subjects. These values declined linearly during the whole study period (see Results).
In the calcium-supplemented subjects, the second maximum was seen earlier, i.e. 8-24 h after dosing. The peak plasma concentration (C raax ) of 8.85 nmol/1 and the area under the serum concentration vs time curve (AUC) of 2279 nmol · h/1 were significantly lower (P < 0.01), but the other pharmacokinetic quantities were unchanged (tab. 1). During the study period, serum calcitriol and calcidiol declined almost linearly from 89.5 ± 12.6 pmol/1 and 44.3 ± 13.5 nmol/1 to 77.8 ± 17.4 pmol/1 and 34.8 ± 10.5 nmol/1, respectively.
In the patients with primary hyperparathyroidism, the initial basal serum concentration of (24A)-hydroxycalcidiol, PR and PR/[calcidiol] ratio (tab. 2) were significantly lower (P < 0.001) than in the healthy non-supplemented subjects of this study (n = 5). The initial half-time in these patients was comparable, but the post-dosing half-time was significantly increased (P < 0.001) (tab. 2). At month 9, the serum concentrations of (24/?)-hydroxycalcidiol and calcidiol were significantly higher than the pre-dosing values (P < 0.02) (tab. 2).
The effect of exogenous (24^)-hydroxycalcidiol on the quantities of calcium and vitamin D metabolism was also studied. A short-term and transient increase of calcitriol was found, especially in subject 5 (tab. 3). Tab. 3. The plasma concentrations of calcitriol and calcidiol after oral administration of 100 μg of (24A)-hydroxycalcidiol to the non-supplemented healthy subjects. (n = 9) and the healthy subjects from I.e. (5) (n = 4) were taken together, because these groups were not statistically different with regard to the plasma concentrations of calcidiol and (24R)-hydroxycalcidiol.
None of the biochemical conditions studied was affected by exogenous (24/?)-hydroxycalcidiol.
Discussion
The terminal half-time (t 1/2 ) and the systemic clearance (Cl) of (24/?)-hydfoxycalcidiol in the non-supplemented healthy subjects after oral administration are comparable to the values found by our group (5) for intravenously administered (24 J R)-hydroxycalcidiol. Kanis et al. (3) found half-times of 9 and 34 days after iv administration of 100 g of (24/?)-hydroxycalcidiol to two healthy subjects. The much shorter half-times found by Kumar et al. (4) most probably represent the distribution half-times, because collection of the blood samples was limited to 6 h after administration of (247?)-hydroxycalcidiol. On the other hand, these authors (4) observed that after administration of tritiated (24/?)-hydroxycalcidiol about 60% of the radioactivity was excreted in faeces and urine up to day 7, suggesting a half-time of 5.3 days, which is comparable to the half-time found in the present study.
In contrast to the plasma concentration vs time curves of intravenously administered (24A)-hydroxycalcidiol (5), the plasma concentration vs time curves after oral administration of (24/?)-hydroxycalcidiol exhibited a second maximum (day 2 -3) in 3 subjects ( fig. 1 ). In principle, this maximum might be due to: a) formation of a metabilite of (24jR)-hydroxycalcidiol with a higher affinity than (247?)-hydroxycalcidiol for the vitamin D binding protein present in the rat plasma used for the assay of (24R)-hydroxycalcidiol; b) enterohepatic cycling of (24J?)-hydroxycalcidiol; c) binding of (24/?)-hydroxycalcidiol in intestinal cells (26, 27) followed by a slow concentrationdependent release into the circulation; d) (partial) uptake of (24jR)rhydroxycalcidiol, like vitamin D 3 (28) and calcidiol (29) , via the lymph system and subsequent (slow) release into plasma; and e) rectal absorption. Since a second maximum was not observed after iv administration of (24A)-hydroxycalcidiol (5), this maximum might be due to a metabolite which is produced exclusively in intestinal tissue and also coassayed in our assay procedure for (24/?)-hydroxycalcidiol. Because rechromatography in a second Chromatographie system did not affect the determined concentrations of (24/?)-hydroxycalcidiol, formation of such a metabolite is not likely. This finding is consistent with the observation that the terminal half-times for iv and oral (247?)-hydroxycalcidiol are comparable.
An enterohepatic cycling is strongly suggested by data in humans (4) and reported for (24/?)-hydroxycalcidiol in rats (30) . Enterohepatic cycling related maxima are also observed, however, after iv administration. Moreover, this explanation is unlikely in view of the time at which the maximum was observed. For the same reason, involvement of rectal absorption can be excluded. Thus, binding by intestinal cells and (partial) uptake via the lymph system are still plausible explanations.
To estimate the fraction of absorbed (247?)-hydroxycalcidiol, that participates in one of the above hypothetical processes, the difference between the area under the total serum concentration vs time curve (AUCj) (tab. 1) and the area under the curve without the second maximum (AUC 2 ) was calculated. Based upon this difference, 3% of measured (24JR)-hydroxycalcidiol as estimated from (AUC 1 -AUC 2 )/AUC 1 , appeared to be involved.
We (5) found earlier that iv administration of 25 g of (24/?)-hydroxycalcidiol resulted in an AUC of 1374 nmol · h/1. Assuming linear pharmacokinetics, this will mean that iv administration of 100 g of (24J?)-hydroxycalcidiol will result in an AUC of 5496 nmol · h/1 and that the bioavailability of (24l?)-hydroxycalcidiol after an oral dose of 100 g is 72%.
This estimate agrees well with a bioavailability of about 70%, as determined earlier by us (5).
The significantly higher initial basal concentration and production rate of (24jR)-hydroxycalcidiol in subject 3 are at least in part explained by the higher plasma concentration of calcidiol, the metabolic precursor of (24/?)-hydroxycalcidiol. In this subject, (24/?)-hydroxycalcidiol was produced at a higher rate from calcidiol, as reflected in the PR/[calcidiol] ratio which was increased 4-fold (tab. 2). This provides an explanation for the elevated basal concentration.
The production rate of 1.3 + 0.4 g/day is comparable to the production rate of calcitriol (31) . The much lower plasma concentration of calcitriol is due to its higher clearance as estimated from reported data (31).
In the calcium-supplemented subjects, the clearance and production rate of (24/?)-hydroxycalcidiol were unchanged, implying that clearance and production rate of this metabolite are not affected by calcium supplementation in these subjects. The significantly lower AUC will mean that the bioavailability of oral (24/?)-hydroxycalcidiol is decreased under conditions of calcium supplementation, possibly due to: a) decreased (active) uptake of the metabolite; b) more extensive metabolism of (24jR)-hydroxycalcidiol by intestinal cells due to an effect of the calcium supplementation on the activity of the metabolizing enzymes; and c) an effect of calcium supplementation on the receptor of calcitriol known to have some affinity for (24/?)-hydroxycalcidiol (30).
Since calcium supplementation would result in raised serum calcidiol (32) , the observed decrease of calcidiol represents a seasonal effect. Because calcitriol does not show a clear seasonal variation during JanuaryMarch (33), the observed decrease of calcitriol was at least in part due to calcium supplementation, which is known to depress calcitriol (32) .
In the patients with primary hyperparathyroidism, basal concentration at month 9 was significantly higher than its initial value. This was possibly due to a significant seasonal increase of calcidiol (tab. 2) (P < 0.01) at the end of the study (May-July). The reason for the significant change of half-time remains to be clarified.
The low production rate in patients with primary hyperparathyroidism was in part due to the lower serum concentration of calcidiol (tab. 2). The PR/ [calcidiol] ratio was 5 -10 fold lower in these patients, accounting for the lower serum concentration of (24/?)-hydroxycalcidiol. The production rate of (24,R)-hydroxycalcidiol was lower in these patients despite significantly higher serum concentrations of calcitriol, which are known to stimulate production of (247?)-hydroxycalcidiol (7-11).
The low plasma concentrations of (24/?)-hydroxycalcidiol and the high plasma concentrations of calcitriol in patients with primary hyperparathyroidism were in line with a) inhibition of the renal 24-hydroxylase activity by parathyroid hormone (parathyrin) (6-8) and b) the stimulation of renal loc-hydroxylase by parathyroid hormone (parathyrin) (34) .
The strong positive correlation between plasma concentrations of (24<R)-hydroxycalcidiol and calcidiol is consistent with earlier studies of our group (33, 35) . In patients with primary hyperparathyroidism, the regression line was displaced to the right, implicating a threshold concentration of about 15 nmol/1 above which (24jR)-hydroxycalcidiol is produced from calcidiol. In healthy subjects this concentration may be close to 0 (33, 35) . The threshold concentration explained the significantly lower PR/[calcidiol] ratios (tab. 2) and serum concentrations of (24R)-hydroxycalcidiol (tab. 2) in the patients with primary hyperparathyroidism.
Though the observed depression of the production rate is not clinically relevant, it may reflect physiologically relevant changes in vitamin D 3 metabolism.
In subject 5, an acute and large elevation of serum calcitriol (tab. 3) was seen. The values found for the quality control samples did not parallel this change. Moreover, the observed acute elevation cannot be attributed to diurnal variation, which is less than 20% (36), or to changes in dietary intake of calcium and/ or phosphate, which cause smaller changes of calcitriol (37) . Serum calcium, phosphate and parathyroid hormone (parathyrin) were not markedly affected in this subject. A smaller but marked rise of serum calcitriol was also observed previously by us in other subjects (5) . The reasons for these changes of serum calcitriol remains to be clarified.
Exogenous (24/?)-hydroxycalcidiol had no effect on the other quantities of calcium metabolism studied.
In conclusion, a) exogenous (24A)-hydroxycalcidiol has no clear effect on calcium and vitamin D metabolism, b) clearance and production rate of (24jR)-hydroxycalcidiol are not affected by calcium supplementation, c) bioavailability is lower in the calcium-supplemented state and d) in patients with primary hyperparathyroidism the basal serum concentration of (24^)-hydroxycalcidiol is significantly decreased, due primarily to a threshold concentration of about 15 nmol/1 for synthesis of (24A)-hydroxycalcidiol, which is reflected in a significantly lower PR/[calcidiol] ratio.
